ArticlePloS one2026
Uncovering the molecular landscape of young-onset diffuse gastric cancer: A relieff-based feature selection analysis on RNA-Seq data.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiffuse Gastric Cancer (DGC) is an aggressive subtype with a poor prognosis and a lack of specific biomarkers, representing a critical unmet need in oncology. This study aimed to elucidate the key molecular drivers of DGC by integrating RNA-seq data with a multi-faceted bioinformatics approach.
methodsWe analyzed RNA-seq data from young-onset DGC and normal tissues (GSE113255, GSE122401). Machine learning (ML) feature selection (ReliefF algorithm) was used to prioritize genes, followed by protein-protein interaction network analysis to identify hub genes. Their roles were further investigated through Gene Ontology, KEGG pathway analysis, tumor microenvironment immune infiltration, miRNA-regulatory network analysis, transcription factor prediction, and computational drug repurposing analyses.
resultsOur ML‑driven approach identified seven hub genes central to DGC pathogenesis including CCL5, CXCR4, MMP9, FOXP3, IL18, TNFSF11, and TNFSF13B. Among these, three prioritized core hub genes (CXCR4, MMP9, and TNFSF13B) were selected based on statistically significant overexpression and complementary functional roles. Specifically, CXCR4 showed a Fold Change of 3.12 (Log2FC = 1.64, FDR = 0.01), MMP9 exhibited the highest magnitude of upregulation (Fold Change = 16.58, Log2FC = 4.05), and TNFSF13B demonstrated the most statistically significant differential expression (Fold Change = 2.32, Log2FC = 1.21, FDR < 0.000001). High CXCR4 expression was identified as a potential prognostic indicator associated with poorer overall survival in the TCGA‑STAD cohort (HR = 1.5, p = 0.0072). We delineated a core regulatory circuitry where NF‑κB (NFKB1/RELA) masterfully regulates the hub gene network. Drug repurposing analysis nominated several FDA‑approved agents, including the VEGF‑A inhibitor Bevacizumab, which indirectly suppresses CXCR4 and MMP9.
conclusionThis pilot study establishes a robust integrative framework that synergizes ML with network biology. It nominates CXCR4 and TNFSF13B as candidate therapeutic targets and highlights the potential of ML‑based feature selection for discovering biologically relevant, context‑dependent prognostic indicators in DGC. However, we emphasize that these findings are exploratory and hypothesis‑generating, requiring independent validation through experimental studies and larger cohorts before any clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.